Ocular Therapeutix, Inc.
Clinical trials sponsored by Ocular Therapeutix, Inc., explained in plain language.
Ocular Therapeutix, Inc.
OCUL
NASDAQ
Biopharmaceutical company developing therapies for eye diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye implant could slow vision loss in diabetes Results expected Mar 2027 (estimated) 🚀 Make-or-break